Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market